Literature DB >> 26376654

Location of brain tumor intersecting white matter tracts predicts patient prognosis.

Nikolai J Mickevicius1, Alexander B Carle2, Trevor Bluemel2, Stephanie Santarriaga2, Fallon Schloemer3, Derrick Shumate3, Jennifer Connelly3, Kathleen M Schmainda1,2, Peter S LaViolette4,5.   

Abstract

Brain tumor cells invade adjacent normal brain along white matter (WM) bundles of axons. We therefore hypothesized that the location of tumor intersecting WM tracts would be associated with differing survival. This study introduces a method, voxel-wise survival analysis (VSA), to determine the relationship between the location of brain tumor intersecting WM tracts and patient prognosis. 113 primary glioblastoma (GBM) patients were retrospectively analyzed for this study. Patient specific tumor location, defined by contrast-enhancement, was combined with diffusion tensor imaging derived tractography to determine the location of axons intersecting tumor enhancement (AXITEs). VSA was then used to determine the relationship between the AXITE location and patient survival. Tumors intersecting the right anterior thalamic radiation (ATR), right inferior fronto-occipital fasciculus (IFOF), right and left cortico-spinal tract (CST), and corpus callosum (CC) were associated with decreased overall survival. Tumors intersecting the CST, body of the CC, right ATR, posterior IFOF, and inferior longitudinal fasciculus are associated with decreased progression-free survival (PFS), while tumors intersecting the right genu of the CC and anterior IFOF are associated with increased PFS. Patients with tumors intersecting the ATR, IFOF, CST, or CC had significantly improved survival prognosis if they were additionally treated with bevacizumab. This study demonstrates the usefulness of VSA by locating AXITEs associated with poor prognosis in GBM patients. This information should be included in patient-physician conversations, therapeutic strategy, and clinical trial design.

Entities:  

Keywords:  Brain tumor; Diffusion; Glioblastoma; White matter tracts

Mesh:

Substances:

Year:  2015        PMID: 26376654      PMCID: PMC6094943          DOI: 10.1007/s11060-015-1928-5

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  40 in total

1.  Voxel-based lesion-symptom mapping.

Authors:  Elizabeth Bates; Stephen M Wilson; Ayse Pinar Saygin; Frederic Dick; Martin I Sereno; Robert T Knight; Nina F Dronkers
Journal:  Nat Neurosci       Date:  2003-05       Impact factor: 24.884

2.  Brain fiber tracking with clinically feasible diffusion-tensor MR imaging: initial experience.

Authors:  Kei Yamada; Osamu Kizu; Susumu Mori; Hirotoshi Ito; Hisao Nakamura; Sachiko Yuen; Takao Kubota; Osamu Tanaka; Wataru Akada; Hiroyasu Sasajima; Katsuyoshi Mineura; Tsunehiko Nishimura
Journal:  Radiology       Date:  2003-04       Impact factor: 11.105

3.  Improved optimization for the robust and accurate linear registration and motion correction of brain images.

Authors:  Mark Jenkinson; Peter Bannister; Michael Brady; Stephen Smith
Journal:  Neuroimage       Date:  2002-10       Impact factor: 6.556

4.  Prognostic significance of preoperative MRI scans in glioblastoma multiforme.

Authors:  M A Hammoud; R Sawaya; W Shi; P F Thall; N E Leeds
Journal:  J Neurooncol       Date:  1996-01       Impact factor: 4.130

5.  Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: a radiographic study in 358 de novo human glioblastomas.

Authors:  Benjamin M Ellingson; Timothy F Cloughesy; Whitney B Pope; Taryar M Zaw; Heidi Phillips; Shadi Lalezari; Phioanh L Nghiemphu; Hassana Ibrahim; Kourosh M Naeini; Robert J Harris; Albert Lai
Journal:  Neuroimage       Date:  2011-10-07       Impact factor: 6.556

6.  Prognostic factors influencing clinical outcomes of glioblastoma multiforme.

Authors:  Shou-wei Li; Xiao-guang Qiu; Bao-shi Chen; Wei Zhang; Huan Ren; Zhong-cheng Wang; Tao Jiang
Journal:  Chin Med J (Engl)       Date:  2009-06-05       Impact factor: 2.628

7.  Migratory patterns of lac-z transfected human glioma cells in the rat brain.

Authors:  P H Pedersen; K Edvardsen; I Garcia-Cabrera; R Mahesparan; J Thorsen; B Mathisen; M L Rosenblum; R Bjerkvig
Journal:  Int J Cancer       Date:  1995-09-15       Impact factor: 7.396

8.  Probabilistic radiographic atlas of glioblastoma phenotypes.

Authors:  B M Ellingson; A Lai; R J Harris; J M Selfridge; W H Yong; K Das; W B Pope; P L Nghiemphu; H V Vinters; L M Liau; P S Mischel; T F Cloughesy
Journal:  AJNR Am J Neuroradiol       Date:  2012-09-20       Impact factor: 3.825

9.  Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma.

Authors:  W B Pope; A Lai; R Mehta; H J Kim; J Qiao; J R Young; X Xue; J Goldin; M S Brown; P L Nghiemphu; A Tran; T F Cloughesy
Journal:  AJNR Am J Neuroradiol       Date:  2011-02-17       Impact factor: 3.825

10.  Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma.

Authors:  Daniel A Hamstra; Thomas L Chenevert; Bradford A Moffat; Timothy D Johnson; Charles R Meyer; Suresh K Mukherji; Douglas J Quint; Stephen S Gebarski; Xiaoying Fan; Christina I Tsien; Theodore S Lawrence; Larry Junck; Alnawaz Rehemtulla; Brian D Ross
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-02       Impact factor: 11.205

View more
  9 in total

1.  Decreased survival in glioblastomas is specific to contact with the ventricular-subventricular zone, not subgranular zone or corpus callosum.

Authors:  Akshitkumar M Mistry; Michael C Dewan; Gabrielle A White-Dzuro; Philip R Brinson; Kyle D Weaver; Reid C Thompson; Rebecca A Ihrie; Lola B Chambless
Journal:  J Neurooncol       Date:  2017-01-10       Impact factor: 4.130

Review 2.  Gliomas Infiltrating the Corpus Callosum: A Systematic Review of the Literature.

Authors:  Paolo Palmisciano; Gianluca Ferini; Gina Watanabe; Christian Ogasawara; Emal Lesha; Othman Bin-Alamer; Giuseppe E Umana; Kenny Yu; Aaron A Cohen-Gadol; Tarek Y El Ahmadieh; Ali S Haider
Journal:  Cancers (Basel)       Date:  2022-05-19       Impact factor: 6.575

Review 3.  Surgical oncology for gliomas: the state of the art.

Authors:  Nader Sanai; Mitchel S Berger
Journal:  Nat Rev Clin Oncol       Date:  2017-11-21       Impact factor: 66.675

4.  Predicting patterns of failure in temporal lobe GBMs: possible implications on radiotherapy treatment portals.

Authors:  Dasantha Jayamanne; Helen Wheeler; David Brazier; Allison Newey; Marina Kastelan; Linxin Guo; Michael Back
Journal:  Radiat Oncol       Date:  2018-07-20       Impact factor: 3.481

5.  Brain MRI imaging characteristics predict treatment response and outcome in patients with de novo brain metastasis of EGFR-mutated NSCLC.

Authors:  Chia-Ying Lin; Chao-Chun Chang; Po-Lan Su; Chien-Chung Lin; Yau-Lin Tseng; Wu-Chou Su; Yi-Ting Yen
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

6.  Untapped Neuroimaging Tools for Neuro-Oncology: Connectomics and Spatial Transcriptomics.

Authors:  Jurgen Germann; Gelareh Zadeh; Alireza Mansouri; Walter Kucharczyk; Andres M Lozano; Alexandre Boutet
Journal:  Cancers (Basel)       Date:  2022-01-18       Impact factor: 6.639

Review 7.  White Matter Tracts and Diffuse Lower-Grade Gliomas: The Pivotal Role of Myelin Plasticity in the Tumor Pathogenesis, Infiltration Patterns, Functional Consequences and Therapeutic Management.

Authors:  Hugues Duffau
Journal:  Front Oncol       Date:  2022-03-02       Impact factor: 6.244

Review 8.  Involvement of White Matter Language Tracts in Glioma: Clinical Implications, Operative Management, and Functional Recovery After Injury.

Authors:  Alexander A Aabedi; Jacob S Young; Edward F Chang; Mitchel S Berger; Shawn L Hervey-Jumper
Journal:  Front Neurosci       Date:  2022-07-11       Impact factor: 5.152

Review 9.  Glioblastoma Treatments: An Account of Recent Industrial Developments.

Authors:  Edouard Alphandéry
Journal:  Front Pharmacol       Date:  2018-09-13       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.